Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and ... Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
4 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
12 | 0 | 0 | 7.539 | 7.539 | 7.539 | 0 | 0 | CS |
26 | -0.1435 | -1.86788154897 | 7.6825 | 8.6345 | 5.4355 | 1289277 | 6.82409481 | CS |
52 | 3.241 | 75.4071661238 | 4.298 | 14.595 | 2.835 | 7127211 | 6.27438295 | CS |
156 | -639.961 | -98.8356756757 | 647.5 | 1470 | 2.835 | 3599203 | 83.32351411 | CS |
260 | -2109.961 | -99.6439669421 | 2117.5 | 5862.5 | 2.835 | 2747394 | 368.07818439 | CS |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관